Search

Your search keyword '"Rosellini, Sara"' showing total 6 results
Start Over Author "Rosellini, Sara"
6 results on '"Rosellini, Sara"'

1. P553: PRELIMINARY RESULTS OF MRD ANALYSIS OF AML1718, A PHASE 2 OPEN-LABEL STUDY OF VENETOCLAX, FLUDARABINE, IDARUBICIN AND CYTARABINE (V-FLAI) IN THE INDUCTION THERAPY OF NON LOW-RISK AML

Author

Minetto, Paola, primary, Guolo, Fabio, additional, Rosellini, Sara, additional, Piciocchi, Alfonso, additional, Marconi, Giovanni, additional, Audisio, Ernesta, additional, Priolo, Giorgio, additional, Papayannidis, Cristina, additional, Martelli, Maurizio, additional, Paoloni, Francesca, additional, Bocchia, Monica, additional, Lanza, Francesco, additional, Lico, Albana, additional, Ciceri, Fabio, additional, Giovanni Della Porta, Matteo, additional, Frigeni, Marco, additional, Giaccone, Luisa, additional, Beltrami, Germana, additional, Borlenghi, Erika, additional, Chiara DI Chio, Maria, additional, Selleri, Carmine, additional, Crea, Enrico, additional, Urbino, Irene, additional, Sartor, Chiara, additional, Minotti, Clara, additional, Arena, Valentina, additional, Nanni, Jacopo, additional, Simonetti, Giorgia, additional, Teresa Bochicchio, Maria, additional, Saglio, Giuseppe, additional, Venditti, Adrianno, additional, Vignetti, Marco, additional, Fazi, Paola, additional, Tedone, Elisabetta, additional, Martinelli, Giovanni, additional, and Massimo Lemoli, Roberto, additional

Published
2023
Full Text
View/download PDF

2. Single Agent Tagraxofusp in Relapsed/Refractory CD123-Positive Acute Myeloid Leukemia: A Preliminary Analysis of Italian Gimema AML2020 Trial

Author

Minetto, Paola, Rosellini, Sara, Guolo, Fabio, Tedone, Elisabetta, Audisio, Ernesta, Cattaneo, Chiara, Bocchia, Monica, Fracchiolla, Nicola, Martelli, Maria Paola, Crea, Enrico, Carminati, Enrico, Gorreo Renzulli, Livia, Fugazza, Giuseppina, Piciocchi, Alfonso, Ottonelli, Giovanni, Miglino, Maurizio, Cea, Michele, Curti, Antonio, Pagano, Livio, Venditti, Adriano, Mughal, Tariq, and Lemoli, Roberto Massimo

Published
2023
Full Text
View/download PDF

3. Centralized MRD Assessment at Early Timepoints in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk AML

Author

Minetto, Paola, Guolo, Fabio, Rosellini, Sara, Piciocchi, Alfonso, Marconi, Giovanni, Audisio, Ernesta, Priolo, Giorgio, Papayannidis, Cristina, Martelli, Maurizio, Paoloni, Francesca Paola, Bocchia, Monica, Lanza, Francesco, Lico, Albana, Ciceri, Fabio, Della Porta, Matteo Giovanni, Frigeni, Marco, Giaccone, Luisa, Beltrami, Germana, Borlenghi, Erika, Di Chio, Maria Chiara, Selleri, Carmine, Crea, Enrico, Urbino, Irene, Sartor, Chiara, Minotti, Clara, Arena, Valentina, Nanni, Jacopo, Simonetti, Giorgia, Bochicchio, Maria Teresa, Saglio, Giuseppe, Venditti, Adriano, Vignetti, Marco, Fazi, Paola, Tedone, Elisabetta, Martinelli, Giovanni, and Lemoli, Roberto M.

Published
2023
Full Text
View/download PDF

4. Final Analysis for the Primary End-Point of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Author

Marconi, Giovanni, Piciocchi, Alfonso, Audisio, Ernesta, Papayannidis, Cristina, Guolo, Fabio, Cerrano, Marco, Arena, Valentina, Saveria, Capria, Rondoni, Michela, Della Porta, Matteo Giovanni, Beltrami, Geramana, Bocchia, Monica, Lico, Albana, Giaccone, Luisa, Rossi, Marianna, Califano, Catello, Carrabba, Matteo Giovanni, Cattaneo, Chiara, Frigeni, Marco, Di Chio, Maria Chiara, Serio, Bianca, Freilone, Roberto, Curti, Antonio, Minetto, Paola, Marsili, Giovanni, Minotti, Clara, Zannetti, Beatrice, Cotugno, Francesca, Nanni, Jacopo, Simonetti, Giorgia, Bochicchio, Maria Teresa, Rosellini, Sara, Tedone, Elisabetta, Venditti, Adriano, Lemoli, Roberto Massimo, Vignetti, Marco, Fazi, Paola, and Martinelli, Giovanni

Published
2023
Full Text
View/download PDF

6. Comparing Outcomes Between CPX-351 and Fludarabine-Based Induction in Secondary Acute Myeloid Leukemia in the Real-World Setting: The Prognostic Role of Measurable Residual Disease.

Author

Riva C, Minetto P, Chies M, Vernarecci C, Colombo N, Rosellini S, Parodi A, Tedone E, Carminati E, Nurra C, Puglisi F, Frello M, Maio E, Ferro B, Zecchetti G, Fugazza G, Nozza P, Cea M, Lemoli RM, and Guolo F

Subjects
Aged, Female, Humans, Male, Middle Aged, Cytarabine administration & dosage, Cytarabine therapeutic use, Prognosis, Remission Induction, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myeloid, Acute mortality, Leukemia, Myeloid, Acute therapy, Leukemia, Myeloid, Acute pathology, Neoplasm, Residual, Vidarabine analogs & derivatives, Vidarabine administration & dosage, Vidarabine therapeutic use
Abstract

Secondary acute myeloid leukemia (s-AML) is associated with inferior outcomes with conventional chemotherapy, and fludarabine combinations (FLAG-Ida) have been tested to improve results. More recently, CPX-351 resulted superior to conventional 3 + 7 in s-AML patients. In the UK NCRI AML19 trial, AML patients were randomized to receive either FLAG-Ida or CPX-351. Subgroup analysis revealed better overall survival (OS) with CPX-351 in patients with MDS-related gene mutations. Unfortunately, minimal residual disease (MRD) was evaluated only in a minority of patients. The aim of this study was to further disclose the mechanisms of higher efficacy of CPX-351 in s-AML, with a focus on MRD. We analyzed 183 consecutive s-AML elderly patients (median age 69, range 60-77) treated with CPX-351 (n = 82) or receiving FLAG-Ida (n = 101). Complete remission (CR) rate and MRD negativity probability were higher among patients receiving CPX-351 (MRD negative CR rate of 40/64, 62.5%, compared to 25/55, 45% in patients who received FLAG-Ida, p < 0.05). Extra-hematological toxicity was lower in CPX-351 arm, and 30 days mortality was 3.6% and 8% in patients receiving CPX-351 or FLAG-Ida, respectively. Notably, 21/64 (32.8%) CR patients treated with CPX 351 underwent allogeneic stem cell transplantation (HSCT), compared to 5/55 with FLAG-Ida (9%, p < 0.05). Overall, CPX-351 treatment resulted in higher OS (median OS 17.7 vs. 11.2 months with FLAG-Ida, p < 0.05). The better outcome of CPX-351 compared to FLAG-Ida in our cohort may be explained by a greater probability of MRD negativity, alongside with an improved tolerance, enabling more s-AML patients to undergo HSCT., (© 2024 John Wiley & Sons Ltd.)

Published
2025
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results